INDIANAPOLIS and BOSTON, June 17,
2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
and Dana-Farber Cancer Institute today announced a multiyear
collaboration to research new medicines under development to fight
cancer.
"Working together is the most powerful approach in fighting
cancer," said Richard Gaynor, M.D.,
senior vice president, product development and medical affairs,
Lilly Oncology. "Lilly's partnership with Dana-Farber demonstrates an open,
collaborative research approach—uniting the expertise of the
pharmaceutical industry with that of a leading academic cancer
research institution."
Per the agreement, over the course of three years Dana-Farber will provide research and
development expertise for a number of early-stage Lilly oncology
compounds. Dana-Farber researchers
and Lilly scientists will work collaboratively on preclinical and
clinical studies, molecular studies of patient samples and the
design and conduct of clinical trials, which may result in
important advances in the science of cancer care. The agreement
also allows Dana-Farber scientists
to conduct independent studies on select Lilly compounds. Following
research conducted at Dana-Farber,
the evaluated compounds will still be fully owned by Lilly.
Financial terms of the agreement are not being disclosed.
"This is a new kind of collaboration between a comprehensive
cancer center and a large pharmaceutical company," said
Barrett Rollins, M.D., Ph.D., chief
scientific officer of Dana-Farber.
"Under this agreement, Lilly can access the expertise within
Dana-Farber to help it develop
multiple preclinical and clinical compounds. Together, we can bring
compounds to clinical trials and to FDA approval quickly and
efficiently, and thus benefit our patient population."
About Dana-Farber Cancer Institute
Dana-Farber Cancer
Institute, a principal teaching affiliate of Harvard Medical
School, is world-renowned for its leadership in adult and
pediatric cancer treatment and research. Designated as a
comprehensive cancer center by the National Cancer Institute
(NCI), it is one of the largest recipients among independent
hospitals of NCI and National Institutes of Health grant funding.
For more information, go to www.dana-farber.org.
About Lilly Oncology
For more than fifty years, Lilly
has been dedicated to delivering life-changing medicines and
support to people living with cancer and those who care for them.
Lilly is determined to build on this heritage and continue making
life better for all those affected by cancer around the world. To
learn more about Lilly's commitment to people with cancer, please
visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels. C-LLY
Lilly Forward-Looking Statement
This press release contains "forward-looking statements" (as that
term is defined in the United
States Private Securities Litigation Reform Act of 1995)
regarding the potential of cancer research and development at
Lilly. This press release reflects Lilly's current beliefs.
However, there are substantial risks and uncertainties in the
process of drug research, development, and commercialization. Among
other risks, there can be no guarantee that these compounds will
receive regulatory approval, or, if approved, that it will achieve
intended benefits or become a commercially successful product. For
further discussion of these and other risks and uncertainties that
could cause actual results to differ materially from Lilly's
expectations, please see the company's latest Forms 10-K and 10-Q
filed with the U.S. Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements.
Refer to:
Karen
Glowacki; kglowacki@lilly.com; (317) 370-1177; (Lilly
Oncology);
Ellen Berlin;
ellen_berlin@dfci.harvard.edu; (617) 632-4090; (Dana-Farber)
Photo -
http://photos.prnewswire.com/prnh/20150616/223392LOGO
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-and-dana-farber-cancer-institute-announce-research-collaboration-300100176.html
SOURCE Eli Lilly and Company